Open AccessExperience with the use of enalapril in children and adolescents with diabetic nephropathy and a normative level of blood pressure
Author(s) -
Г. И. Сивоус,
Э. П. Касаткина,
V. N. Sokolovskaya,
Emma Anatolievna Voychik,
Т. М. Алексеева,
L P Pashintseva
Publication year - 1997
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl199743519-22
Subject(s) - medicine , microalbuminuria , enalapril , proteinuria , albuminuria , blood pressure , diabetic nephropathy , nephropathy , urology , diabetes mellitus , endocrinology , angiotensin converting enzyme , kidney
In order to study the efficacy of APP inhibitors in the treatment of diabetic nephropathy, 42 patients (13 men and 29 women) aged 11.6 to 20.9 years with diabetic nephropathy and normal arterial pressure were administered enalapril (“Renitek”) in a daily dose of 5 to 10 mg for 3 to 9 months. The treatment efficacy was assessed from the time course of albuminunuria and proteinuria, level of glycated hemoglobin HbAl, and arterial pressure values. Out of 35 patients with microalbuminuria treated for 3 to 9 months, albuminuria decreased in 32 (91.1%), and in 28 of these (80%) normalized. Out of 7 patients with proteinuria it notably decreased in 6, and in one patient albuminuria normalized. The results persisted for 9 months in the majority of cases after the drug was discontinued. Arterial pressure did not change much. Hence, enalapril is an effective drug for the treatment of diabetic nephropathy with microalbuminuria and proteinuria in normotensive patients.